@article{mbs:/content/journal/jgv/10.1099/vir.0.039909-0, author = "Greggs, Willie M. and Clouser, Christine L. and Patterson, Steven E. and Mansky, Louis M.", title = "Discovery of drugs that possess activity against feline leukemia virus", journal= "Journal of General Virology", year = "2012", volume = "93", number = "4", pages = "900-905", doi = "https://doi.org/10.1099/vir.0.039909-0", url = "https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.039909-0", publisher = "Microbiology Society", issn = "1465-2099", type = "Journal Article", abstract = "Feline leukemia virus (FeLV) is a gammaretrovirus that is a significant cause of neoplastic-related disorders affecting cats worldwide. Treatment options for FeLV are limited, associated with serious side effects, and can be cost-prohibitive. The development of drugs used to treat a related retrovirus, human immunodeficiency virus type 1 (HIV-1), has been rapid, leading to the approval of five drug classes. Although structural differences affect the susceptibility of gammaretroviruses to anti-HIV drugs, the similarities in mechanism of replication suggest that some anti-HIV-1 drugs may also inhibit FeLV. This study demonstrates the anti-FeLV activity of four drugs approved by the US FDA (Food and Drug Administration) at non-toxic concentrations. Of these, tenofovir and raltegravir are anti-HIV-1 drugs, while decitabine and gemcitabine are approved to treat myelodysplastic syndromes and pancreatic cancer, respectively, but also have anti-HIV-1 activity in cell culture. Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use.", }